Edition:
United States

PharmAthene Inc (PIP.A)

PIP.A on American Stock Exchange

0.76USD
21 Apr 2017
Change (% chg)

$-0.01 (-1.76%)
Prev Close
$0.78
Open
$0.77
Day's High
$0.80
Day's Low
$0.76
Volume
58,845
Avg. Vol
303,971
52-wk High
$3.50
52-wk Low
$0.48

PIP.A

Chart for PIP.A

About

Pharmathene, Inc. (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA)... (more)
No analyst recommendations are available for PIP.A.

Overall

Beta: 3.11
Market Cap(Mil.): $52.64
Shares Outstanding(Mil.): 68.82
Dividend: 2.91
Yield (%): --

Financials

  PIP.A Industry Sector
P/E (TTM): 0.26 57.54 29.95
EPS (TTM): 2.92 -- --
ROI: 1,031.56 -0.41 13.21
ROE: 1,073.74 6.21 14.38

BRIEF-Pharmathene files for mixed shelf of up to $100 Mln

* Files for mixed shelf of up to $100 million - sec filing Source text : http://bit.ly/2odSp57 Further company coverage:

Mar 30 2017

BRIEF-Pharmathene reports FY earnings per share $2.95

* Pharmathene reports year-end 2016 financial and operational results

Mar 14 2017

BRIEF-Blank check company Matlin & Partners Acquisition Corp files for IPO of up to $300 million - SEC Filing

* Blank check company Matlin & Partners Acquisition Corp files for IPO of up to $300 million - SEC Filing Source text for Eikon: [http://bit.ly/2kztUcz] Further company coverage: [Matlin & Paterson Acquisition Co]

Feb 15 2017

BRIEF-Pharmathene to pay Altimmune termination fee of $2 mln upon termination of deal

* Pharmathene -upon termination of deal under limited specified circumstances following receipt of superior offer, co to pay Altimmune termination fee of $2 million Source text (http://bit.ly/2k4rmUa) Further company coverage:

Jan 19 2017

BRIEF-Pharmathene & Altimmune announces merger

* Pharmathene and Altimmune announce merger to create immunotherapeutics company targeting infectious diseases

Jan 19 2017

BRIEF-PharmAthene declares $2.91 special cash dividend on common stock

* PharmAthene declares $2.91 special cash dividend on common stock Source text for Eikon: Further company coverage:

Nov 17 2016

BRIEF-Pharmathene has received final payment from Siga Technologies

* Has received final payment from Siga Technologies Inc of $83.9 million which fully satisfies judgment owed to Pharmathene

Nov 16 2016

BRIEF-PharmAthene reports Q3 earnings per share $1.67

* If SIGA pays Co cash in full on judgment,barring unexpected material events, intends to distribute at least 90% of after tax proceeds of payment to shareholders

Nov 04 2016

More From Around the Web

Competitors

  Price Chg
Green Cross Corp (006280.KS) ₩164,000.00 +500.00
Pfizer Inc. (PFE.N) $33.64 -0.10
Panacea Biotec Limited (PNCA.NS) Rs164.05 +4.70
Bavarian Nordic A/S (BAVA.CO) kr.347.00 -16.50
Emergent Biosolutions Inc (EBS.N) $28.57 -0.53
Ibio Inc (IBIO.A) $0.40 -0.01
Soligenix Inc (SNGX.OQ) $4.15 +0.56
Pfenex Inc (PFNX.A) $4.58 -0.04

Earnings vs. Estimates